Ampio Pharmaceuticals, Inc. (AMPE)
Levi & Korsinsky, LLP announces that a AMPE class action lawsuit has been filed on behalf of investors who purchased Ampio Pharmaceuticals, Inc. (AMPE) common stock between December 29, 2020 and August 3, 2022. For more on the AMPE Lawsuit please contact us today.
According to the Ampio Pharmaceuticals, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(i) defendants had inflated the Company’s true ability to successfully file a Biologics License Application (“BLA”) for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants’ statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Ampio Pharmaceuticals, Inc. you have until October 17, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Ampio Pharmaceuticals, Inc. Class Action Lawsuit
Ampio Pharmaceuticals, Inc. Lawsuit
AMPE Class Action Lawsuit
Ampio Pharmaceuticals, Inc. (AMPE) Class Action Lawsuit